Potential risk factors
| |
MTX problems
|
---|
| |
Feel sick before taking MTX
|
Feel sick after taking MTX
|
Vomit after taking MTX
|
Anxious about blood tests
|
Anxious about injections
|
---|
|
n
|
Unadjusted Exp(β) (95% CI)
|
Adjusted Exp (β) † (95% CI)
|
Unadjusted Exp(β) (95% CI)
|
Adjusted Exp (β) † (95% CI)
|
Unadjusted Exp(β) (95% CI)
|
Adjusted Exp (β) † (95% CI)
|
Unadjusted Exp(β) (95% CI)
|
Adjusted Exp (β) † (95% CI)
|
Unadjusted Exp(β) (95% CI)
|
Adjusted Exp (β) † (95% CI)
|
---|
Age
|
171
|
1.10 (1.01–1.19)
|
1.06 (0.92–1.22)
|
1.15 (1.06–1.24)
|
1.11 (0.98–1.25)
|
1.06 (0.97–1.17)
|
1.07 (0.92–1.24)
|
0.82 (0.75–0.90)
|
0.76 (0.65-0.89)
|
0.85 (0.79–0.93)
|
0.83 (0.73–0.95)
|
Sex
| | | | | | | | | | | |
Male
|
48
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
Female
|
123
|
0.56
|
0.89
|
1.06
|
1.38
|
0.52
|
0.48
|
1.18
|
0.87
|
0.79
|
0.78
|
(0.28–1.15)
|
(0.37–2.16)
|
(0.54–2.08)
|
(0.62–3.09)
|
(0.24–1.16)
|
(0.19–1.25)
|
(0.58–2.42)
|
(0.35-2.18)
|
(0.40–1.55)
|
(0.32–1.88)
|
MTX current route
| | | | | | | | | | | |
Oral
|
71
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
Subcutaneous
|
100
|
2.51
|
2.33
|
1.39
|
1.50
|
3.21
|
3.75
|
1.25
|
0.79
|
2.40
|
2.31
|
(1.21–5.19)
|
(0.96–5.66)
|
(0.75–2.58)
|
(0.69–3.26)
|
(1.31–7.89)
|
(1.28–11.06)
|
(0.66–2.40)
|
(0.34-1.87)
|
(1.27–4.54)
|
(1.02–5.22)
|
MTX current dose (mg)
|
171
|
1.10
|
1.06
|
1.11
|
1.06
|
1.05
|
0.98
|
0.95
|
1.10
|
0.96
|
1.03
|
(1.02–1.19)
|
(0.95–1.19)
|
(1.04–1.20)
|
(0.96–1.17)
|
(0.97–1.14)
|
(0.88–1.10)
|
(0.88–1.02)
|
(0.97-1.25)
|
(0.89–1.02)
|
(0.93–1.15)
|
Duration of MTX use in months
|
168
|
1.02
|
1.01
|
1.01
|
1.01
|
1.02
|
1.01
|
0.98
|
0.996
|
0.995
|
1.00
|
(1.01 - 1.03)
|
(0.99-1.03)
|
(1.00- 1.03)
|
(0.99-1.02)
|
(1.00 -1.03)
|
(0.99-1.03)
|
(0.97-0.997)
|
(0.98-1.01)
|
(0.98 - 1.01)
|
(0.98 - 1.01)
|
Taking folic acid
| | | | | | | | | | | |
No
|
24
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
Yes
|
124
|
0.41
|
0.55
|
0.48
|
0.68
|
0.41
|
0.57
|
1.02
|
0.98
|
0.76
|
0.42
|
(0.17 – 1.01)
|
(0.19 – 1.58)
|
(0.20 – 1.17)
|
(0.25 – 1.85)
|
(0.16 – 1.08)
|
(0.18 – 1.76)
|
(0.41 – 2.59)
|
(0.32 - 3.03)
|
(0.27 – 1.60)
|
(0.14 – 1.25)
|
Current disease severity:
| | | | | | | | | | | |
No. active joints
|
158
|
1.24
|
1.29
|
1.07
|
1.09
|
1.07
|
0.91
|
1.20
|
1.15
|
1.23
|
1.40
|
(1.06 – 1.44)
|
(1.05 – 1.60)
|
(0.92 – 1.23)
|
(0.91 – 1.30)
|
(0.91 – 1.25)
|
(0.74 – 1.13)
|
(0.97 – 1.29)
|
(0.95 - 1.40)
|
(1.03 – 1.46)
|
(1.09 – 1.79)
|
No. limited joints
|
155
|
1.09
|
1.01
|
1.01
|
0.95
|
1.09
|
1.04
|
0.97
|
0.97
|
0.98
|
0.93
|
| |
(0.99 – 1.20)
|
(0.91 – 1.12)
|
(0.92 – 1.10)
|
(0.85 – 1.06)
|
(0.99 – 1.21)
|
(0.92 – 1.17)
|
(0.88 – 1.08)
|
(0.85 - 1.10)
|
(0.90 – 1.07)
|
(0.82 – 1.06)
|
- †Adjusted for all variables simultaneously.
- Exp(β) – predicted change in odds for a one unit increase in the predictor variable.
- Statistically significant findings in the adjusted analyses are shown in bold.